<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01746225</url>
  </required_header>
  <id_info>
    <org_study_id>IBCSG 42-12 / BIG 2-12</org_study_id>
    <secondary_id>2012-003058-10</secondary_id>
    <nct_id>NCT01746225</nct_id>
  </id_info>
  <brief_title>Schedules of Nab-Paclitaxel in Metastatic Breast Cancer</brief_title>
  <acronym>SNAP</acronym>
  <official_title>A Randomized Phase II Study Evaluating Different Schedules of Nab-Paclitaxel in Metastatic Breast Cancer (SNAP Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Breast Cancer Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Breast International Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>International Breast Cancer Study Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Longer first line chemotherapy duration has recently been associated with a modest, but
      significant improvement in overall survival and a clinically meaningful and statistically
      significant improvement in progression-free survival, in metastatic breast cancer patients.
      Prolonging chemotherapy until disease progression, however, must be weighed against the
      detrimental effects of continuous chemotherapy delivery. The SNAP trial seeks to improve the
      tolerability of prolonged chemotherapy administration strategy by studying alternative
      treatment schedules, while preserving and possibly improving treatment efficacy in this
      disease setting.

      The availability of a new nanoparticle albumin-bound taxane, nab-Paclitaxel (Abraxane®),
      represents an opportunity to test this hypothesis. Nab-Paclitaxel has been developed in an
      attempt to reduce the toxicity associated with standard taxane administration (caused by the
      use of chemical solvents) while increasing antitumor efficacy.

      The SNAP randomized phase II trial evaluates three schedules of nab-Paclitaxel as prolonged
      chemotherapy administration strategy. Each of three arms will be compared to a historical
      reference of seven-month median progression-free survival (PFS) based on the most recent
      trial with docetaxel as control arm to determine whether any of the three arms are worthy of
      further investigation.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of nab-Paclitaxel schedules</measure>
    <time_frame>At the end of the third induction cycle and during maintenance nab-Paclitaxel every three months until PD (an expected average of nine months)</time_frame>
    <description>Disease response and progression will be evaluated according to the revised Response Evaluation Criteria in Solid Tumors (RECIST V 1.1) Patients may have measurable or non-measurable disease. CT can is the method to measure lesion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerability, feasibility, disease response and OS of nab-Paclitaxel schedules</measure>
    <time_frame>Targeted AEs at the end of each cycle and hematology days 1, 8, 15, 22 according to treatment arm</time_frame>
    <description>Determination of targeted adverse events (AE), performance status, hematological/ biochemical examinations and physical exams are used to evaluate tolerability and feasibility, vital signs for overall survival (OS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>QL self-assessment once each months until PD (maximal twelve months, expected average of nine months) and at end-of-treatment visit</time_frame>
    <description>To explore the changes in quality of life (QL) over time until treatment discontinuation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognostic biomarker analysis</measure>
    <time_frame>SPARC and caveolin expressions will be determined in FFPE (formalin fixed paraffin embedded) samples from primary tumor (obtained 14 days prior to randomization) and from FFPE sample of metastatic biopsy at PD (an expected average of nine months)</time_frame>
    <description>To investigate the prognostic role of putative markers (SPARC and caveolin) and assess any change in the expression of SPARC and caveolin between primary and the metastatic sites.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">258</enrollment>
  <condition>Metastatic Breastcancer</condition>
  <arm_group>
    <arm_group_label>nab-Paclitaxel 150 mg/m2 days 1,15</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm A: Induction nab-Paclitaxel 125 mg/m2 on days 1,8,15 every 28 days for 3 cycles followed by maintenance nab-Paclitaxel 150 mg/m2 administered on days 1, 15 of each 28-day cycle (total 300mg/m2 per cycle) until progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>nab-Paclitaxel 100 mg/m2 days 1,8,15</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm B: Induction nab-Paclitaxel 125 mg/m2 on days 1,8,15 every 28 days for 3 cycles followed by maintenance nab-Paclitaxel 100 mg/m2 administered on days 1, 8, 15 of each 28-day cycle (total 300mg/m2 per cycle) until progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>nab-Paclitaxel 75 mg/m2 days 1,8,15,22</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm C: Induction nab-Paclitaxel 125 mg/m2 on days 1,8,15 every 28 days for 3 cycles followed by maintenance nab-Paclitaxel 75 mg/m2 administered on days 1, 8, 15, 22 of each 28-day cycle (total 300mg/m2 per cycle) until progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nab-Paclitaxel</intervention_name>
    <description>Induction phase: 3 cycles of nab-Paclitaxel days 1, 8, 15. Maintenance phase with three maintenance schedules of nab-Paclitaxel (same total dose per cycle, different number of administrations)</description>
    <arm_group_label>nab-Paclitaxel 150 mg/m2 days 1,15</arm_group_label>
    <arm_group_label>nab-Paclitaxel 100 mg/m2 days 1,8,15</arm_group_label>
    <arm_group_label>nab-Paclitaxel 75 mg/m2 days 1,8,15,22</arm_group_label>
    <other_name>Abraxane</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed HER2-negative metastatic (stage IV) breast
             cancer.

          -  Measurable or non-measurable, but radiologically evaluable, disease according to
             RECIST 1.1 criteria.

          -  Female aged 18 years or older.

          -  Life expectancy &gt; 3 months.

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.

          -  Either ER-positive or ER-negative disease. Patients with ER-positive disease must be
             endocrine resistant, defined as having failed at least one prior endocrine therapy for
             breast cancer, or must be candidates for first-line chemotherapy.

          -  If previously treated with a taxane or anthracycline in the neoadjuvant or adjuvant
             setting, the period from end of treatment to disease recurrence must have been &gt; 12
             months (&gt; 365 days).

          -  Radiation therapy, if given and regardless of site, must be completed at least 2 weeks
             prior to randomization.

          -  Normal hematologic status.

          -  Normal renal function.

          -  Normal liver function.

          -  Normal cardiac function.

          -  Women of childbearing potential: documented negative pregnancy test within 2 weeks
             prior to randomization, and acceptable birth control during the duration of the trial
             therapy and for a period of 6 months following the last administration of study drug.

          -  Written Informed Consent (IC) must be signed and dated by the patient and the
             Investigator prior to randomization.

          -  Completed baseline Quality of Life Form.

          -  The patient has been informed of and agrees to data transfer and handling, in
             accordance with national data protection guidelines.

          -  Availability of an formalin fixed paraffin embedded (FFPE) block from the primary
             tumor (breast lesion) for submission to central pathology review and for translational
             research.

          -  Written consent to pathology material submission, signed and dated by the patient and
             the Investigator prior to randomization.

        Exclusion Criteria:

          -  Any prior chemotherapy for metastatic breast cancer.

          -  Presence of central nervous system (CNS) metastasis.

          -  Peripheral neuropathy grade 2 or higher (CTCAE version 4).

          -  Significant uncontrolled cardiac disease (i.e. unstable angina, recent myocardial
             infarction within prior 6 months), patients classified as having a New York Heart
             Association (NYHA) class III or IV congestive heart failure.

          -  Pregnant or lactating.

          -  Prior history of non-breast malignancy (except for adequately controlled basal cell
             carcinoma of the skin, carcinoma in situ of the cervix, in situ carcinoma of the
             bladder).

          -  Any concurrent condition which in the Investigator's opinion makes it inappropriate
             for the patient to participate in the trial or which would jeopardize compliance with
             the protocol.

          -  Contraindications or known hypersensitivity to the study medication or excipients.

          -  The use of any anti-cancer investigational agents within 30 days prior to expected
             start of trial treatment.

          -  Inability or unwillingness to abide by the study protocol or cooperate fully with the
             Investigator.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alessandra Gennari, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Division of Medical Oncology, E.O. Galliera, Genoa, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guy Jerusalem, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>CHU Sart Tilman and University of Liège, Liège, Belgium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHR de la Citadelle, Oncology-Haematology Unit</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Sart Tilman, Medical Oncology</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Peltzer-La Tourelle, Department of Clinical Cancerology</name>
      <address>
        <city>Verviers</city>
        <zip>4800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bon Secours</name>
      <address>
        <city>Cork</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cork University Hospital</name>
      <address>
        <city>Cork</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beaumont Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mater Misericordiae University Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mater Private Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St James's Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Vincent's University Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Galway</name>
      <address>
        <city>Galway</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid-Western Regional Hospital</name>
      <address>
        <city>Limerick</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Waterford Regional Hospital</name>
      <address>
        <city>Waterford</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera SS Antonio e Biagio</name>
      <address>
        <city>Alessandria</city>
        <zip>15121</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale degli Infermi</name>
      <address>
        <city>Biella</city>
        <zip>13900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uo Medicina Ocologica Ospedale Di Carpri e Mirandola, Azienda USL di Modena</name>
      <address>
        <city>Carpi/ Modena</city>
        <zip>41012</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>E.O. Ospedali Galliera</name>
      <address>
        <city>Genova</city>
        <zip>16128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo di Oncologia (IEO)</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Salvatore Maugeri</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. Oncologia, AUSL Rimini</name>
      <address>
        <city>Rimini</city>
        <zip>47923</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita degli Studi di Roma La Sapienza</name>
      <address>
        <city>Roma</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS MultiMedica</name>
      <address>
        <city>Sede di Castellanza</city>
        <zip>21053</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Osp. Universitaria di Udine</name>
      <address>
        <city>Udine</city>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale di Circolo e Fondatione Macchi</name>
      <address>
        <city>Varese</city>
        <zip>21100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Oncology</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall D'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consorcop Hospitalario Provincial De Castellon</name>
      <address>
        <city>Castellon</city>
        <zip>12002</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Arnau De Vilanova De Lleida</name>
      <address>
        <city>Lleida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Sant Joan De Reus</name>
      <address>
        <city>Tarragona</city>
        <zip>43204</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Lozano Blesa De Zaragoza</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Aarau</name>
      <address>
        <city>Aarau</city>
        <zip>5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Oncologico della Svizzera Italiana</name>
      <address>
        <city>Bellinzona</city>
        <zip>6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsspital/ Inselspital Bern</name>
      <address>
        <city>Bern</city>
        <zip>3011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalzentrum Biel</name>
      <address>
        <city>Biel</city>
        <zip>2501</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Graubünden</name>
      <address>
        <city>Chur</city>
        <zip>7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Baselland</name>
      <address>
        <city>Liestal</city>
        <zip>4410</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Luzerner Kantonsspital</name>
      <address>
        <city>Luzern</city>
        <zip>6000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologiezentrum Thun-Berner Oberland</name>
      <address>
        <city>Thun</city>
        <zip>3600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Winterthur</name>
      <address>
        <city>Witerthur</city>
        <zip>8401</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Slovenia</country>
    <country>Spain</country>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Chia SK, Speers CH, D'yachkova Y, Kang A, Malfair-Taylor S, Barnett J, Coldman A, Gelmon KA, O'reilly SE, Olivotto IA. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer. 2007 Sep 1;110(5):973-9.</citation>
    <PMID>17647245</PMID>
  </reference>
  <reference>
    <citation>Gennari A, Conte P, Rosso R, Orlandini C, Bruzzi P. Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies. Cancer. 2005 Oct 15;104(8):1742-50.</citation>
    <PMID>16149088</PMID>
  </reference>
  <reference>
    <citation>Andre F, Slimane K, Bachelot T, Dunant A, Namer M, Barrelier A, Kabbaj O, Spano JP, Marsiglia H, Rouzier R, Delaloge S, Spielmann M. Breast cancer with synchronous metastases: trends in survival during a 14-year period. J Clin Oncol. 2004 Aug 15;22(16):3302-8.</citation>
    <PMID>15310773</PMID>
  </reference>
  <reference>
    <citation>Dawood S, Broglio K, Gonzalez-Angulo AM, Buzdar AU, Hortobagyi GN, Giordano SH. Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer. J Clin Oncol. 2008 Oct 20;26(30):4891-8. doi: 10.1200/JCO.2007.14.1168. Epub 2008 Aug 25.</citation>
    <PMID>18725649</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 28, 2012</study_first_submitted>
  <study_first_submitted_qc>December 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2012</study_first_posted>
  <last_update_submitted>May 29, 2017</last_update_submitted>
  <last_update_submitted_qc>May 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic</keyword>
  <keyword>Breast</keyword>
  <keyword>Cancer</keyword>
  <keyword>HER2-negative Stage IV</keyword>
  <keyword>No previous chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

